Keytruda 25 mg/mL Sterile solution for infusion.
PDF Leaflet Revision Date: 12 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including melanoma, NSCLC, and classical Hodgkin lymphoma.
Dosage (summary)
200 mg IV every 3 weeks or 400 mg IV every 6 weeks for adults; 2 mg/kg (max 200 mg) for pediatric patients.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding; potential fetal harm.
Key Drug Interactions
- Corticosteroids may interfere with efficacy
- Avoid immunosuppressants before treatment
Contraindications
- Hypersensitivity to pembrolizumab
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Immune-mediated reactions
Counselling Points
- Monitor for immune-mediated side effects
- Report any severe reactions
- Use contraception during treatment
Serious warnings
- Severe immune-mediated adverse reactions
- Pneumonitis
- Colitis
- Hepatitis
- Nephritis
Important Disclaimer
The Keytruda 25 mg/mL Sterile solution for infusion. professional information leaflet below is the property of Msd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
